
Stérimar is a French nasal hygiene brand owned by Church & Dwight Co., Inc. (NYSE: CHD) through its Sofibel SAS subsidiary. Laboratoires Fumouze launched it in 1975 as the first seawater-based nasal spray, and it remains the leading non-medicated nasal hygiene spray in France and the United Kingdom, sold in more than 80 countries through pharmacy channels.
Parent Company
Acquired
2001
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Stérimar | Church & Dwight Co., Inc. | Wholly owned |
Stérimar's story begins with Laboratoires Fumouze, a Paris pharmacy house whose origins trace to 1804, when the Albespeyres pharmacy opened on rue du Faubourg Saint-Denis. The Fumouze family took over in 1835 and built the business into a recognized French pharmaceutical laboratory.
In 1975 Fumouze developed and brought Stérimar to market, the first application of seawater in physiological concentration to nasal hygiene. The concept was simple: purified seawater, with its natural salts, minerals and trace elements, washes out nasal cavities without drugs, steroids or preservatives. It found immediate acceptance in French pharmacies, a channel where the Fumouze name carried weight.
The brand pioneered what became an entire OTC category. Competitors entered with their own seawater sprays, but Stérimar kept leadership through product extensions: hypertonic congestion relief formulas, allergy variants, and dedicated baby and kids lines safe from birth and three months respectively.
In 2001 Church & Dwight acquired the business, folding Laboratoires Fumouze into Sofibel SAS as its pharmaceutical arm and gaining international distribution infrastructure. Under Church & Dwight, Stérimar expanded past France to more than 80 countries and became the UK's leading GP-recommended non-medicated nasal spray.
The seawater itself still comes from the Bay of Cancale off the Brittany coast, a sourcing detail the brand treats as core to its identity, with UK-market products manufactured in the United Kingdom.
What does Church & Dwight own?
Church & Dwight owns eight power brands: Arm & Hammer (baking soda, laundry detergent, household cleaners, cat litter), Trojan (condoms), Oxi-Clean (stain removers), Waterpik (oral care), Therabreath (mouthwash), Hero (acne care), Touchland (hand sanitizer), and Batiste (dry shampoo). The company also owns additional brands including First Response, Nair, Orajel, Xtra, and Zicam. In 2025, the company divested its VitaFusion and L'il Critters vitamin brands.
Is Church & Dwight publicly traded?
Yes, Church & Dwight Co., Inc. is publicly traded on the New York Stock Exchange under ticker symbol CHD. The company went public in 1969 and is a component of the S&P 500 Index.
Who founded Church & Dwight?
Church & Dwight was founded in 1846 by Austin Church, a physician, and John Dwight, a businessman, in New York, New York. They established a partnership to manufacture sodium bicarbonate, commonly known as baking soda, and introduced the Arm & Hammer brand in 1867.
Where is Church & Dwight headquartered?
Church & Dwight is headquartered in Ewing, New Jersey, USA. The company has manufacturing facilities in the United States, Canada, Mexico, Brazil, and China.
How many brands does Church & Dwight own?
Church & Dwight owns eight power brands: Arm & Hammer, Trojan, Oxi-Clean, Waterpik, Therabreath, Hero, Touchland, and Batiste. The company also markets additional brands including First Response, Nair, Orajel, Xtra, and Zicam.
Who owns Church & Dwight?
Church & Dwight is publicly owned with a dispersed shareholder base. Institutional investors hold the majority of shares, with no single controlling shareholder. Major institutional shareholders include Vanguard Group, BlackRock, and State Street Global Advisors, typical of S&P 500 companies.
What is Church & Dwight's revenue?
For FY2025, Church & Dwight reported net sales of $6,203.2 million, up 1.6% from $6,107.1 million in FY2024. Net income was $736.8 million, or $3.02 per diluted share. Adjusted EPS was $3.53, up 2.6% from 2024.
Has Church & Dwight made major acquisitions recently?
Yes. In 2025, Church & Dwight acquired the Touchland hand sanitizer brand for $700 million at closing plus up to $180 million in earnout, for a total purchase price of up to $880 million. Touchland became the company's eighth power brand. The company also divested its VitaFusion and L'il Critters vitamin brands to Piping Rock on December 31, 2025, and exited its Flawless, SpinBrush, and Waterpik showerhead businesses.
The brand has pursued packaging reduction, cutting plastic content roughly 15 percent, and has partnered with marine environmental organizations, a natural fit given its seawater sourcing story. Parent Church & Dwight reports group-level sustainability programs covering packaging and emissions.
The product's drug-free, preservative-free formulation is itself positioned as the health-conscious alternative in the category, though it holds no major independent certifications such as B Corp or Leaping Bunny.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Emergent Biosolutions | USA | 2014 | Mass market | United states | All Genders |
Market Positioning: Stérimar competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Church & Dwight Co., Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram is privately owned, unlike Stérimar which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
23andMe is privately owned, unlike Stérimar which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
Band-Aid is privately owned, unlike Stérimar which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
Boots is privately owned, unlike Stérimar which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
Duane Reade is privately owned, unlike Stérimar which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Konsyl Pharmaceuticals Inc.
Psyllium fiber supplement brand produced by Konsyl Pharmaceuticals, a privately held Maryland company marketing the same psyllium active ingredient as Metamucil since 1934.
Konsyl is privately owned, unlike Stérimar which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.